Osaka, Japan, November 2, 2016 --- Takeda Pharmaceutical Company Limited (TSE: 4502) today issued a following statement regarding today's media articles.
Today, certain media reported Takeda is negotiating with Valeant Pharmaceutical International Inc. about acquisition of its gastroenterology business unit. These articles are not based on any announcement by Takeda.
Takeda is continuously considering various options aiming to accelerate its growth focusing on prioritized therapeutic areas of gastroenterology, oncology and central nervous system plus vaccines. At any given time, Takeda is in discussion with many parties in these therapeutic areas. At this point, we have nothing to be disclosed. When any agreement is reached, we disclose the agreement in a timely manner.
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news/.
Additional information about Takeda is available through its corporate website, http://betterhealth.takeda.com/.
+81 (0) 3-3278-2417
Internal Disclaimer Body